10x Genomics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $642.8M | $610.8M | $593.23B | $536.57B | $491.26B | $248.98B | $245.69B | $204.52B |
| Instruments | — | — | $222.59B | $233.51B | $204.37B | $95.07B | $95.66B | $63.95B |
| Consumables | — | — | $322.75B | $254.33B | $260.81B | $145.72B | $143.43B | $138.54B |
| Service | — | — | $47.90B | $48.73B | $26.08B | $8.20B | $6.60B | $2.03B |
| Cost of Revenue | $198.9M | $196.3M | $209.4M | $120.4M | $74.1M | $58.5M | $61.0M | $28.7M |
| Gross Profit | $443.9M | $414.5M | $409.3M | $396.0M | $416.4M | $240.4M | $184.9M | $117.7M |
| Gross Margin | 69.1% | 67.9% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $316.1M | $344.3M | $343.3M | $298.3M | $257.6M | $202.3M | $130.8M | $87.9M |
| Operating Income | $-61.0M | $-194.6M | $-265.3M | $-167.9M | $-52.3M | $-534.1M | $-30.6M | $-110.8M |
| Operating Margin | -9.5% | -31.9% | 0.0% | 0.0% | 0.0% | -0.2% | 0.0% | -0.1% |
| Interest Expense | — | — | $33.0K | $476.0K | $866.0K | $1.7M | $3.1M | $2.4M |
| Pretax Income | $-39.9M | $-177.7M | $-248.8M | $-162.0M | $-53.7M | $-534.5M | $-31.0M | $-112.4M |
| Income Tax Expense | $3.6M | $4.9M | $6.3M | $4.0M | $4.5M | $8.3M | $218.0K | $87.0K |
| Net Income | $-43.5M | $-182.6M | $-255.1M | $-166.0M | $-58.2M | $-542.7M | $-31.3M | $-112.5M |
| Net Margin | -6.8% | -29.9% | 0.0% | 0.0% | 0.0% | -0.2% | 0.0% | -0.1% |
| EPS (Basic) | $-0.35 | $-1.52 | $-2.18 | $-1.46 | $-0.53 | $-5.37 | $-0.27 | $-2.80 |
| EPS (Diluted) | $-0.35 | $-1.52 | $-2.18 | $-1.46 | $-0.53 | $-5.37 | $-0.27 | $-2.80 |
| Shares Outstanding (Basic) | 124.7M | 120.5M | 117.2M | 113.9M | 110.3M | 101.2M | 117.3M | 43.6M |
| Shares Outstanding (Diluted) | 124.7M | 120.5M | 117.2M | 113.9M | 110.3M | 101.2M | 117.3M | 43.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |